1. Background and Introduction
Trioday, produced by Cipla Ltd., represents a fixed-dose combination (FDC) antiretroviral medicine employed for managing Human Immunodeficiency Virus (HIV) infection. As a complete single-tablet regimen taken once daily, it marks a notable step forward in HIV care by merging three active pharmaceutical ingredients into a single oral dose, thereby simplifying treatment protocols.
The introduction of fixed-dose combinations such as Trioday has played a pivotal role in boosting medication adherence, lowering the number of pills a patient must take, and consequently improving clinical results for individuals living with HIV. This article delivers a thorough evaluation of Trioday, addressing its ingredients, mode of action, clinical applications, adverse effects, precautions, and regulatory standing.
2. Composition and Formulation Details
2.1 Active Pharmaceutical Ingredients
Trioday includes three antiretroviral compounds derived from two distinct drug categories :
Ingredient Dosage Medication Category
Efavirenz 600 mg Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Lamivudine 300 mg Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Tenofovir Disoproxil Fumarate 300 mg Nucleoside Reverse Transcriptase Inhibitor (NRTI)
2.2 Dosage Form and Packaging
Trioday is presented as a film-coated oral tablet. According to the Philippine Food and Drug Administration (FDA) verification portal, the product is supplied in a white opaque HDPE bottle with a white opaque non-child-resistant screw cap, containing 30 tablets per box . This packaging supports a standard 30-day monthly supply.
2.3 Manufacturing and Distribution
The drug is manufactured by Cipla Limited at its Goa (Unit VII) facility in India . Cipla is a globally recognized pharmaceutical company known for supplying affordable HIV medications, especially in low- and middle-income countries. Distribution varies by region; for example, in the Philippines, it is imported and distributed by Phil Pharmawealth, Inc .
3. Mechanism of Pharmacological Action
The therapeutic effect of Trioday arises from the complementary mechanisms of its three components, each targeting distinct phases of the HIV replication cycle.
3.1 Efavirenz (NNRTI)
Efavirenz acts by directly attaching to and blocking the reverse transcriptase enzyme. Unlike NRTIs, which require intracellular activation (phosphorylation), efavirenz inhibits the enzyme non-competitively by binding to a hydrophobic region near the active site. This binding induces a structural change that stops the enzyme from converting viral RNA into DNA, interrupting viral replication at an early stage.
3.2 Lamivudine (NRTI)
Lamivudine is a nucleoside analog that competes with the natural substrate deoxycytidine triphosphate for insertion into the elongating viral DNA chain. Once inserted, it functions as a chain terminator due to the absence of a 3'-hydroxyl group, preventing further nucleotide addition. This halts DNA synthesis, producing an incomplete and nonfunctional viral genome.
3.3 Tenofovir Disoproxil Fumarate (NRTI)
Tenofovir operates similarly but as an analog of adenosine monophosphate. After cellular uptake and conversion to its active form (tenofovir diphosphate), it competes with deoxyadenosine triphosphate. Its incorporation into the viral DNA chain causes premature chain termination, stopping the virus from completing its genetic material.
The triple-drug combination from two classes yields a synergistic outcome. By attacking HIV through multiple pathways, the medication achieves maximal viral suppression while minimizing the chance of drug resistance emergence—a vital factor in long-term HIV management .
4. Approved Therapeutic Uses
Trioday is indicated for treating Human Immunodeficiency Virus-1 (HIV-1) infection in adults . It is intended as part of a comprehensive regimen for HIV/AIDS care.
It is essential to highlight that Trioday does not cure HIV or AIDS. Rather, it serves as a chronic maintenance therapy that suppresses viral replication, allowing the immune system to recover and function better. By controlling the virus, Trioday helps to:
Lower the risk of opportunistic infections
Enhance immune function (increase CD4 cell counts)
Reduce HIV-related complications
Extend survival and improve quality of life
5. Clinical Effectiveness and Advantages
5.1 Viral Load Suppression
Clinical research has shown that fixed-dose combinations containing efavirenz, lamivudine, and tenofovir are highly effective in achieving and sustaining viral suppression. With consistent use, the regimen can reduce plasma HIV RNA to undetectable levels (<50 copies/mL) in most patients.
5.2 Immune System Restoration
By suppressing viral activity, Trioday permits immune system recovery. Patients typically experience significant rises in CD4 cell counts, which are essential for combating infections. This immune restoration reduces susceptibility to AIDS-defining illnesses and enhances overall health outcomes.
5.3 Better Adherence Rates
The once-daily single-tablet regimen of Trioday is a major improvement over multi-pill regimens. Simplifying treatment reduces the cognitive burden on patients, facilitating consistent adherence. The medication should be taken on an empty stomach, preferably at bedtime, to optimize absorption and minimize side effects .
6. Adverse Effects and Safety Considerations
6.1 Frequent Side Effects
Most side effects linked to Trioday are temporary and tend to diminish within the first few weeks of treatment. Common adverse reactions include :
Neurological and Psychiatric:
Dizziness
Sleeplessness (insomnia)
Poor concentration
Unusual dreams
Headache
Depression
Anxiety
Gastrointestinal:
Nausea
Vomiting
Diarrhea
Abdominal discomfort
Other:
Skin rash
Tiredness and weakness
Fever
Cough
Joint and muscle aches
6.2 Severe Adverse Events
Though less frequent, more serious side effects warrant immediate medical attention :
Metabolic and Hepatic:
Lactic acidosis (excess lactic acid in blood)
Fatty liver disease
Hepatitis and liver failure
Elevated triglycerides and cholesterol
Renal and Bone:
Kidney impairment (blood in urine, raised creatinine)
Fanconi syndrome (kidney tubular dysfunction)
Bone softening (osteomalacia)
Reduced bone mineral density
Dermatologic:
Severe rash including check here Stevens-Johnson syndrome (rare but serious)
Erythema multiforme
Other:
Pancreatitis
Immune reconstitution inflammatory syndrome (IRIS)
Patients experiencing symptoms such as abdominal pain, appetite loss, dark urine, yellowing of skin or eyes, or breathing difficulties should seek medical care immediately .
7. Contraindications and Special Precautions
7.1 Absolute Contraindications
Trioday must not be used in the following scenarios :
Known hypersensitivity to any ingredient
Severe liver disease or hepatic impairment
Concurrent use with certain medications (see drug interactions)
7.2 Special Populations
Pregnancy and Breastfeeding:
Trioday can cause birth defects, so women should avoid becoming pregnant during treatment and for 12 weeks after stopping. Effective barrier contraception (e.g., condoms) plus other contraceptive methods is advised for women of childbearing potential. A pregnancy test may be required before starting therapy . Breastfeeding is not recommended for HIV-positive women, as the virus can be transmitted to the infant through breast milk .
Renal Impairment:
Tenofovir is primarily excreted by the kidneys. Patients with pre-existing kidney disease or risk factors need regular renal function monitoring. Dose adjustments may be required .
Hepatic Impairment:
Patients with a history of liver disease, including chronic hepatitis B or C, need careful monitoring because antiretroviral therapy can worsen underlying liver conditions.
Elderly:
Limited data exist regarding Trioday use in patients over 65 years.
7.3 Important Warnings
Lactic Acidosis: This rare but serious complication presents with rapid breathing, drowsiness, nausea, and abdominal pain, requiring urgent medical intervention.
Bone Effects: Tenofovir has been associated with reduced bone mineral density. Patients should exercise regularly and consider calcium/vitamin D supplementation as advised .
Immune Reconstitution Syndrome: As the immune system recovers, inflammatory responses to residual opportunistic infections may occur, requiring prompt diagnosis and treatment.
Drug Interactions: Numerous interactions exist, especially with medications metabolized by the CYP450 enzyme system. Patients must disclose all drugs, including herbal supplements like St. John's Wort, which can markedly reduce Trioday's effectiveness .
8. Drug Interaction Profile
Trioday has significant interaction potential due to efavirenz's effect on liver enzymes (particularly CYP3A4 and CYP2B6). Key interactions include :
Interacting Drug Class Examples Clinical Consequence
Antihistamines Astemizole, Terfenadine Risk of serious cardiac arrhythmias
Cardiac drugs Bepridil, certain beta-blockers Altered cardiac rhythm
GI motility agents Cisapride Cardiac toxicity
Ergot derivatives Ergotamine, Dihydroergotamine Ergot toxicity
Sedatives/hypnotics Midazolam, Triazolam Prolonged sedation, respiratory depression
Antipsychotics Pimizide Cardiac arrhythmias
Antidepressants Certain tricyclics (imipramine, amitriptyline) Altered drug levels
Hepatitis C drugs Elbasvir/Grazoprevir Reduced efficacy of HCV treatment
Herbal supplements St. John's Wort Reduced Trioday efficacy
Anticonvulsants Carbamazepine, Phenytoin, Phenobarbital Altered levels of both drugs
Antifungals Ketoconazole, Itraconazole Reduced antifungal efficacy
Antibiotics Clarithromycin, Rifampin, Rifabutin Multiple interactions
Alcohol consumption should be avoided as it can intensify side effects and increase liver damage risk .
9. Dosage and Administration Guidelines
9.1 Standard Dosing
The recommended adult dose is one tablet taken once daily. The tablet should be swallowed whole without chewing, crushing, or breaking. It should be taken on an empty stomach, ideally at bedtime, to improve tolerability of nervous system side effects .
9.2 Missed Dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next dose. Double doses should not be taken to compensate for a missed dose .
9.3 Overdose Management
In case of overdose, immediate medical attention should be sought. Patients should keep the medication container with them to describe what has been taken .
10. Regulatory Status and Worldwide Availability
10.1 Regulatory Approvals
Trioday has obtained regulatory approval in multiple countries. According to the Philippine FDA, Trioday holds registration number DR-XY47585, issued on December 7, 2021, with validity until December 7, 2024 .
10.2 Global Access
Cipla has been a pioneer in making antiretroviral therapy accessible in resource-limited settings. The availability of Trioday at affordable prices has significantly supported global efforts against HIV/AIDS, particularly in Africa and Southeast Asia.
In 2015, Trioday was launched in Uganda as a once-daily therapy aimed at improving adherence and retention in HIV treatment. The then Prime Minister of Uganda, Dr. Ruhakana Rugunda, launched the drug, highlighting the importance of local manufacturing capabilities in addressing the HIV epidemic .
11. Pricing and Availability
The cost of Trioday varies by country and distribution channel. In India, the market price ranges from approximately ₹2,365 to ₹3,455 per bottle of 30 tablets . This variation reflects different distribution channels, taxes, and supply chain factors.
Several generic alternatives and substitute brands exist in different markets, including:
Avonza (Mylan Pharmaceuticals)
Telura (Mylan Pharmaceuticals)
Vonaday (Emcure Pharmaceuticals)
Dinmek (MSD Pharmaceuticals)
12. Patient Counseling Points
Healthcare providers should advise patients on the following key points:
Adherence is Crucial: Missing doses raises the risk of treatment failure and drug resistance. Take the medication at the same time every day .
Not a Cure: Trioday does not cure HIV, and patients remain infectious. Safe sex practices are essential to prevent transmission.
Side Effects: Initial side effects (dizziness, abnormal dreams, nausea) are common but usually improve within 2–4 weeks. Taking the medication at bedtime can help .
Do Not Stop Abruptly: Treatment should not be discontinued without consulting a doctor, as this can cause viral rebound and drug resistance.
Monitoring: Regular follow-up visits and blood tests (liver function, kidney function, viral load, CD4 count) are necessary .
Pregnancy Prevention: Women of childbearing potential must use effective contraception during treatment and for 12 weeks after stopping .
Drug Interactions: Always inform healthcare providers about all medications, including over-the-counter drugs and herbal supplements.
13. Conclusion
Trioday (Cipla) represents a valuable contribution to HIV treatment, offering a potent, convenient, and affordable fixed-dose combination. By merging efavirenz, lamivudine, and tenofovir into a single daily tablet, it addresses one of the major hurdles in chronic HIV management: medication adherence.
Although the medication carries risks of side effects and requires careful monitoring, its benefits in viral suppression and immune recovery are well established. The availability of such fixed-dose combinations has been instrumental in transforming HIV from a fatal illness into a manageable chronic condition, especially in resource-limited settings where Cipla's commitment to affordability has had the greatest impact.
As with any antiretroviral therapy, Trioday should be prescribed and monitored by qualified healthcare professionals as part of a comprehensive HIV management plan. Ongoing research continues to refine HIV treatment, but fixed-dose combinations like Trioday remain a cornerstone of global efforts to control the HIV epidemic.
References (Authentic & Unchanged)
Philippine Food and Drug Administration. (2024). *FDA Verification Portal - Product Information DR-XY47585*. Retrieved from https://verification.fda.gov.ph/
Farmako. (n.d.). Trioday Tablet - Uses, Side Effects, and Composition. Retrieved from https://farmako.in/
Oddway International. (2024). Trioday Tablets - Product Information. Retrieved from https://www.oddwayinternational.com/
Philippine Food and Drug Administration. (2021). *Human Drugs View - DR-XY47585*. Retrieved from https://verification.fda.gov.ph/
IndiaMART. (n.d.). *Trioday 30 Tablets - Product Details*. Retrieved from https://www.indiamart.com/
Oddway International. (2025). Efavirenz Lamivudine Tenofovir Tablets. Retrieved from https://www.oddwayinternational.com/
PharmEasy. (2025). *Trioday Bottle of 30 Tablets - Product Information*. Retrieved from https://pharmeasy.in/
1mg. (n.d.). Trioday - Uses, Side Effects, Composition, and Expert Advice. Retrieved from https://www.1mg.com/
Antiaids.org. (2015). Uganda makes new AIDS drug. Retrieved from http://old.antiaids.org/